MoonLake Immunotherapeutics reports results for the quarter ended in June - Earnings Summary

MoonLake Immunotherapeutics

08/08/2024 14:52

* MoonLake Immunotherapeutics  MLTX.OQ  reported a quarterly
adjusted loss of 39 cents​​ per share for the quarter ended in
June, lower than the same quarter last year, when the company
reported EPS of -23 cents.  The mean expectation of
fourteen analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -38 cents
to -22 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * MoonLake Immunotherapeutics's reported EPS for the quarter
was a
loss of 39 cents​.
    * The company reported a quarterly loss of $24.27 million.
    * MoonLake Immunotherapeutics shares had fallen by 2.1% this
quarter and lost 28.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for MoonLake
Immunotherapeutics is $72.00 
This summary was machine generated from LSEG data August 8 at
01:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.28          -0.39          Missed
 Mar. 31 2024      -0.19          -0.22          Missed
 Dec. 31 2023      -0.23          -0.12          Beat
 Sep. 30 2023      -0.23          -0.18          Beat